focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Euronext Growth Dublin Notice

12 Mar 2020 08:00

RNS Number : 6642F
Euronext Dublin
12 March 2020
 

CORPORATE EVENT NOTICE:

Admission Notice

 

OPEN ORPHAN PLC

 

 

LOCATION:

Dublin

 

 

DATE:

12th March 2020

MARKET:

Euronext Growth Dublin

 

 

ADMISSION NOTICE

 

Euronext Dublin approves the admission of the undermentioned securities to trading on Euronext Growth Dublin.

 

OPEN ORPHAN PLC

 

15,600,932 Ordinary Shares GBP 0.001

 

GB00B9275X97 

 

Equity

 

 

 

This announcement has been issued through the Companies Announcement Service of

Euronext Dublin.

 

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided "as is" based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator.

 

The Euronext Markets comprise the markets operated by Euronext Amsterdam, Euronext Brussels, Euronext Dublin, Euronext Lisbon, Euronext Paris and Euronext UK Markets, referred to respectively as the Amsterdam, Brussels, Dublin, Lisbon, Paris and London markets, as relevant.

 

Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at https://www.euronext.com/terms-use.

 

© 2019 Euronext N.V. - All rights reserved

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEFLFLRVSIILII
Date   Source Headline
11th Mar 20217:00 amRNSJournal for Clinical Studies article publication
9th Mar 20217:00 amRNSNew contract win with Oxford BioTherapeutics
26th Feb 20214:58 pmRNSHolding(s) in Company
17th Feb 20219:00 amRNSEthics approval - COVID-19 Human Challenge Study
9th Feb 20213:57 pmRNSHolding(s) in Company
3rd Feb 20217:05 amRNSExercise of Investor Warrants & TVR
3rd Feb 20217:00 amRNSNew challenge study quarantine clinic
1st Feb 20217:00 amRNSContract extension with Carna Biosciences
21st Jan 20217:00 amRNSArticle published in Drug Discovery Today
20th Jan 20217:00 amRNSExpansion of volunteer recruitment centres
11th Jan 20217:00 amRNSFirst volunteer dosed in COVID-19 clinical trial
6th Jan 20214:29 pmRNSHolding(s) in Company
6th Jan 20217:00 amRNSContract renewal with top-3 pharmaceutical client
31st Dec 20207:00 amRNSRule 19.6(c) Confirmation
23rd Dec 20207:00 amRNSSuccessful completion of toxicology study
22nd Dec 20207:00 amRNSContract renewal with top-3 pharmaceutical client
14th Dec 20207:30 amRNSExercise of Share Options
14th Dec 20207:00 amRNSMHRA approval for nasal COVID-19 vaccine trial
7th Dec 20207:00 amRNSVenn Life Sciences contract wins
24th Nov 20207:00 amRNSDirectors Change
19th Nov 20207:00 amRNSCollaboration with HIC-VAC and Wellcome Trust
5th Nov 20207:00 amRNSNew £2.5m Influenza Challenge Study Contract Win
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:10 amRNSExercise of Share Options
30th Oct 20207:00 amRNSNew 2-year contract with a tier 1 German company
20th Oct 20207:00 amRNSContract Signed with UK Government
16th Oct 20208:47 amRNSStatement re further media comment
30th Sep 20207:00 amRNSInterim Results for 6 months ended 30 June 2020
28th Sep 20207:00 amRNSNew £4.3m Challenge Study Contract Win
24th Sep 20207:00 amRNSStatement re price movement and press speculation
23rd Sep 20204:41 pmRNSSecond Price Monitoring Extn
23rd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20207:30 amRNSExercise of Investor Warrants and Issue of Shares
22nd Sep 20207:00 amRNSNew Contract Win
7th Sep 20207:00 amRNShVIVO present at 2020 ERS International Congress
10th Aug 20207:00 amRNSMajor New Contract Win with Top 3 Pharma Company
4th Aug 20207:00 amRNSNew Contract Win with Carna Bioscience ("Carna")
28th Jul 20207:00 amRNSContract for COVID-19 Vaccine Trial
22nd Jul 202012:43 pmRNSResult of AGM
15th Jul 20207:00 amRNSOption to Acquire CHIMagents Limited
10th Jul 20208:00 amRNSEuronext Growth Dublin Notice
8th Jul 20207:00 amRNSUpcoming Investor Events
7th Jul 20207:10 amRNSExercise of Warrants
7th Jul 20207:00 amRNSAdditional Laboratory Services Contracts Signed
26th Jun 20201:05 pmRNSNotice of AGM
24th Jun 20207:00 amRNSResults for the year ended 31 December 2019
17th Jun 20209:33 amEQSHardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020
15th Jun 20207:00 amRNSPositive Phase I results published in The Lancet
12th Jun 20208:00 amRNSEuronext Growth Dublin Notice
11th Jun 202012:15 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.